A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

Clinical trial NCT06673654 · COMPLETED

Trial details

NCT number: NCT06673654
Sponsor: Sun Pharmaceutical Industries, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2023-08-11
Primary completion: 2024-09-23
Enrollment: 476

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.